On the public citation graph

FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO

0 signed · 77 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaoncol.2016.5580openalex-snapshot
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma
inferredcites →https://doi.org/10.1007/s00280-018-3678-5openalex-snapshot
Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
inferredcites →https://doi.org/10.1007/s10120-011-0135-0openalex-snapshot
Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy
inferredcites →https://doi.org/10.1016/j.ejca.2011.06.002openalex-snapshot
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
inferredcites →https://doi.org/10.1016/s0140-6736(18)32557-1openalex-snapshot
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
inferredcites →https://doi.org/10.1016/s0140-6736(82)90466-4openalex-snapshot
CLINICAL TRIALS IN CANCER
inferredcites →https://doi.org/10.1016/s1470-2045(13)70549-7openalex-snapshot
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
inferredcites →https://doi.org/10.1016/s1470-2045(14)70420-6openalex-snapshot
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
inferredcites →https://doi.org/10.1093/annonc/mdw423openalex-snapshot
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial
inferredcites →https://doi.org/10.1093/jjco/hyn078openalex-snapshot
Irinotecan Combined with 5-Fluorouracil and Leucovorin as Second-line Chemotherapy for Metastatic or Relapsed Gastric Cancer
inferredcites →https://doi.org/10.1093/jnci/92.3.205openalex-snapshot
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
inferredcites →https://doi.org/10.1097/00001813-200009000-00003openalex-snapshot
Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel
inferredcites →https://doi.org/10.1159/000217264openalex-snapshot
Paclitaxel, Estramustine and Carboplatin Combination Chemotherapy after Initial Docetaxel-Based Chemotherapy in Castration-Resistant Prostate Cancer
inferredcites →https://doi.org/10.1200/jco.18.01138openalex-snapshot
Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial
inferredcites →https://doi.org/10.1200/jco.1998.16.10.3362openalex-snapshot
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
inferredcites →https://doi.org/10.1200/jco.2011.39.4585openalex-snapshot
Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
inferredcites →https://doi.org/10.1200/jco.2012.48.5805openalex-snapshot
Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial
inferredcites →https://doi.org/10.1634/theoncologist.2018-0602openalex-snapshot
Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis
inferredcites →https://doi.org/10.21037/jgo.2020.03.10openalex-snapshot
Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma—experience at two centres
inferredcites →https://doi.org/10.3322/canjclin.50.1.7openalex-snapshot
Cancer statistics, 2000

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.5016626openalex-extracted
Vasculopathy in the Correa's Cascade of Gastric Cancer: Pathological Features and Phytotherapy Strategy
inferred← citeshttps://doi.org/10.1001/jama.2025.20034openalex-snapshot
Gastric Cancer
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.52830openalex-snapshot
Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma
inferred← citeshttps://doi.org/10.1001/jamaoncol.2023.7262openalex-snapshot
Immunotherapy in Gastric Cancer—Choosing Methods or Results
inferred← citeshttps://doi.org/10.1002/14651858.cd012078.pub2openalex-snapshot
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma
inferred← citeshttps://doi.org/10.1002/ccr3.4009openalex-snapshot
Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
inferred← citeshttps://doi.org/10.1002/ijc.70567openalex-snapshot
Plasma PlGF as a Potential Biomarker in Ramucirumab‐Based Second‐Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial
inferred← citeshttps://doi.org/10.1002/onco.13907openalex-snapshot
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
inferred← citeshttps://doi.org/10.1007/978-981-96-1297-0_33openalex-snapshot
Systemic Therapies for Gastric Cancer
inferred← citeshttps://doi.org/10.1007/s00432-024-05827-xopenalex-snapshot
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)
inferred← citeshttps://doi.org/10.1007/s00761-024-01554-7openalex-snapshot
Systemtherapie des Magenkarzinoms im Stadium IV – aktuelle Entwicklungen
inferred← citeshttps://doi.org/10.1007/s10120-025-01647-1openalex-snapshot
Assessing efficacy of anti-glypican-1 antibody–drug conjugate as potential therapeutic approach for gastric cancer
inferred← citeshttps://doi.org/10.1007/s10120-026-01799-8openalex-snapshot
A multicenter phase II trial of ramucirumab plus irinotecan for early recurrence of gastric cancer during or after adjuvant chemotherapy with docetaxel plus S-1 therapy: the RAMIEL trial (OGSG1901)
inferred← citeshttps://doi.org/10.1007/s10147-023-02376-0openalex-snapshot
Phase I dose-escalation study on irinotecan, cisplatin, and S-1 combination in chemotherapy-naïve patients with HER2-negative advanced gastric cancer (HERBIS-4B, OGSG 1106)
inferred← citeshttps://doi.org/10.1007/s12029-023-00932-5openalex-snapshot
Clinical Outcomes for Previously Treated Patients with Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Literature Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1007/s12029-024-01121-8openalex-snapshot
Network Meta-analysis of Randomized Controlled Trials in Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: Comparisons Involving Ramucirumab
inferred← citeshttps://doi.org/10.1007/s12029-026-01407-zopenalex-snapshot
Relative Clinical Efficacy and Safety of Second- or Later-Line Treatments for Advanced and Metastatic Gastric Cancer: A Rapid Review and Network Meta-Analysis
inferred← citeshttps://doi.org/10.1007/s12032-022-01698-9openalex-snapshot
A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2024.104586openalex-snapshot
Comprehensive review of signaling pathways and therapeutic targets in gastrointestinal cancers
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2025.104617openalex-snapshot
Development of treatment strategies for advanced HER2-positive gastric cancer: Insights from clinical trials
inferred← citeshttps://doi.org/10.1016/j.esmogo.2024.100073openalex-snapshot
Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer
inferred← citeshttps://doi.org/10.1016/s2468-1253(21)00013-3openalex-snapshot
Trifluridine/tipiracil plus ramucirumab in gastric cancer
inferred← citeshttps://doi.org/10.1038/s41571-026-01134-1openalex-snapshot
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics
inferred← citeshttps://doi.org/10.1055/a-2539-0873openalex-snapshot
Medikamentöse Therapiestrategien des Magenkarzinoms
inferred← citeshttps://doi.org/10.1055/s-0044-1790566openalex-snapshot
Gastric Cancer: Molecular Characterization, Therapeutic Innovations, and Perspectives
inferred← citeshttps://doi.org/10.1080/03007995.2024.2366430openalex-snapshot
Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study
inferred← citeshttps://doi.org/10.1080/14796694.2025.2547562openalex-snapshot
New targets and strategies in treatment of metastatic gastric cancer
inferred← citeshttps://doi.org/10.1080/17512433.2025.2551748openalex-snapshot
Pharmacotherapy for previously treated gastric cancer patients: current options and future developments
inferred← citeshttps://doi.org/10.1093/oncolo/oyac086openalex-snapshot
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
inferred← citeshttps://doi.org/10.1097/coc.0000000000001283openalex-snapshot
A Real-World, Propensity-Matched Analysis of Second-Line FOLFIRI-Ramucirumab Versus Ramucirumab-Paclitaxel in Patients With Advanced Upper Gastrointestinal Cancers
inferred← citeshttps://doi.org/10.1177/17588359231173177openalex-snapshot
Emerging targets in gastroesophageal adenocarcinoma: what the future looks like
inferred← citeshttps://doi.org/10.1177/17588359251389741openalex-snapshot
First-line maintenance strategies and later-line options in patients with advanced gastroesophageal adenocarcinoma
inferred← citeshttps://doi.org/10.1186/s12885-023-11004-zopenalex-snapshot
Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)
inferred← citeshttps://doi.org/10.1200/jco.22.02331openalex-snapshot
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
inferred← citeshttps://doi.org/10.1200/jco.24.01119openalex-snapshot
Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial
inferred← citeshttps://doi.org/10.18027/2224-5057-2024-006openalex-snapshot
Efficacy of immunotherapy in advanced gastric cancer: preliminary results of a multicenter observational study
inferred← citeshttps://doi.org/10.18027/2224-5057-2025-15-3s1-38-46openalex-snapshot
Пути повышения эффективности лечения местно-распространенных и метастатических форм злокачественных опухолей желудка на современном этапе
inferred← citeshttps://doi.org/10.21037/atm-20-3265openalex-snapshot
Targeted therapies for gastroesophageal cancers
inferred← citeshttps://doi.org/10.21037/jgo-20-230openalex-snapshot
Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
inferred← citeshttps://doi.org/10.2147/ott.s216047openalex-snapshot
Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data
inferred← citeshttps://doi.org/10.2147/ott.s365505openalex-snapshot
Optimizing the Continuum of Care in Gastric Cancer
inferred← citeshttps://doi.org/10.21873/anticanres.16460openalex-snapshot
Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy – An Update
inferred← citeshttps://doi.org/10.3322/caac.70050openalex-snapshot
Adenocarcinoma of the esophagus and gastroesophageal junction: The evolving treatment landscape for locally advanced and metastatic disease in the era of immune checkpoint inhibitors and biomarker‐driven therapeutics
inferred← citeshttps://doi.org/10.3389/fonc.2023.1072943openalex-snapshot
Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
inferred← citeshttps://doi.org/10.3389/fonc.2024.1419338openalex-snapshot
Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option
inferred← citeshttps://doi.org/10.3389/fonc.2025.1654300openalex-snapshot
Clinical advances and challenges of anti-angiogenic targeted therapy in gastric cancer
inferred← citeshttps://doi.org/10.3390/biom13050796openalex-snapshot
Therapeutic Advances in the Treatment of Gastroesophageal Cancers
inferred← citeshttps://doi.org/10.3390/cancers13061304openalex-snapshot
Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN)
inferred← citeshttps://doi.org/10.3390/cancers13143536openalex-snapshot
How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?
inferred← citeshttps://doi.org/10.3390/cancers16152692openalex-snapshot
Emerging Therapeutic Targets and Future Directions in Advanced Gastric Cancer: A Comprehensive Review
inferred← citeshttps://doi.org/10.3390/cancers16193337openalex-snapshot
Systemic Therapy of Gastric Cancer—State of the Art and Future Perspectives
inferred← citeshttps://doi.org/10.3390/cells14211672openalex-snapshot
Precision Antibody Therapy in Gastric and Gastroesophageal Cancer: Targeting FGFR2b, CLDN18.2, and VEGFR2
inferred← citeshttps://doi.org/10.3390/ijms262311424openalex-snapshot
Therapeutic Frontiers in Gastroesophageal Cancer: Contemporary Concepts in Management and Therapy
inferred← citeshttps://doi.org/10.3390/jcm12093226openalex-snapshot
The Role of Angiogenesis Targeted Therapies in Metastatic Advanced Gastric Cancer: A Narrative Review
inferred← citeshttps://doi.org/10.3390/medicina62050984openalex-snapshot
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis
inferred← citeshttps://doi.org/10.37349/edd.2025.100568openalex-snapshot
Immune checkpoint inhibitors in patients with advanced gastric cancer: a multi-institutional retrospective real-world study
inferred← citeshttps://doi.org/10.56050/01205498.2313openalex-snapshot
Avances presentes y futuros en el tratamiento del cáncer esofagogástrico
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.